Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

The Drug Resistance Profile of Mycobacterium abscessus Group Strains from Korea

  • Received : 2013.06.13
  • Accepted : 2013.08.05
  • Published : 2014.01.02
⟨ Previous Next ⟩

Abstract

Background: Bacteria of the Mycobacterium abscessus group are the second most common pathogens responsible for lung disease caused by nontuberculous mycobacteria in Korea. There is still a lack of studies investigating the genetic mechanisms involved in M. abscessus resistance to antibiotics other than clarithromycin. This study investigated the characteristics of drug resistance exhibited by M. abscessus clinical isolates from Korea. Methods: We performed drug susceptibility testing for a total of 404 M. abscessus clinical strains. Subspecies were differentiated by molecular biological methods and examined for mutations in drug resistance-related genes. Results: Of the 404 strains examined, 202 (50.00%), 199 (49.26%), and 3 (0.74%) strains were identified as M. abscessus, M. massiliense, and M. bolletii, respectively. Of the 152 clarithromycin-resistant strains, 6 possessed rrl mutations, while 4 of the 30 amikacin-resistant strains contained rrs mutations, and 5 of the 114 quinolone-resistant strains had gyr mutations. All mutant strains had high minimal inhibitory concentration values for the antibiotics. Conclusions: Our results showed the distribution of the strains with mutations in drug resistance-related genes was low in the M. abscessus group. Furthermore, we performed drug susceptibility testing and sequence analyses to determine the characteristics of these genes in the M. abscessus group.

Keywords

References

  1. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983;5:657-79. https://doi.org/10.1093/clinids/5.4.657
  2. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993;147:1271-8. https://doi.org/10.1164/ajrccm/147.5.1271
  3. Han XY, Dé I, Jacobson KL. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. Am J Clin Pathol 2007;128:612-21. https://doi.org/10.1309/1KB2GKYT1BUEYLB5
  4. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment of Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52:565-71. https://doi.org/10.1093/cid/ciq237
  5. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902. https://doi.org/10.1164/rccm.200905-0704OC
  6. Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, et al. Outcomes in patients with Mycobacterium abscessuss pulmonary disease treated with long-term injectable drugs. Respir Med 2011;105:781-7. https://doi.org/10.1016/j.rmed.2010.12.012
  7. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 2007;175:367-416. https://doi.org/10.1164/rccm.200604-571ST
  8. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-8. https://doi.org/10.1378/chest.129.2.341
  9. Ryoo SW, Shin S, Shim MS, Park YS, Lew WJ, Park SN, et al. Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans. J Clin Lab Anal 2008;22:415-20. https://doi.org/10.1002/jcla.20278
  10. Kim HY, Kook Y, Yun YJ, Park CG, Lee NY, Shim TS, et al. Proportions of Mycobacterium massiliense and Mycobacterium bolletii strains among Korean Mycobacterium chelonae-Mycobacterium abscessus group isolates. J Clin Microbiol 2008;46:3384-90. https://doi.org/10.1128/JCM.00319-08
  11. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53:1367-76. https://doi.org/10.1128/AAC.01275-08
  12. Kim HY, Kim BJ, Kook Y, Yun YJ, Shin JH, Kim BJ, et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010;54:347-53. https://doi.org/10.1111/j.1348-0421.2010.00221.x
  13. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-10. https://doi.org/10.1164/rccm.201003-0395OC
  14. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved Standard, M24-A2. Wayne, PA: CLSI, 2011.
  15. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996;40:1676-81.
  16. Nash KA and Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995;39:2635-30. https://doi.org/10.1128/AAC.39.12.2635
  17. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998;177:1573-81. https://doi.org/10.1086/515328
  18. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998;42:2084-8.
  19. Adékambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006;56:133-43. https://doi.org/10.1099/ijs.0.63969-0
  20. Adekambi T, Reynaud-Gaubert M, Greub G, Gevaudan MJ, La Scola B, Raoult D, et al. Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004;42:5493-501. https://doi.org/10.1128/JCM.42.12.5493-5501.2004
  21. Nash KA and Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995;39:2625-30. https://doi.org/10.1128/AAC.39.12.2625
  22. Coleman K, Athalye M, Clancey A, Davison M, Payne DJ, Perry CR, et al. Bacterial resistance mechanisms as therapeutic targets. J Antimicrob Chemother 1994;33:1091-116. https://doi.org/10.1093/jac/33.6.1091
  23. Fierro JF, Hardisson C, Salas JA. Involvement if cell impermeability in resistance to macrolides in some producer streptomycetes. J Antibiot 1988;41:142-4. https://doi.org/10.7164/antibiotics.41.142
  24. Banerjee SK, Bhatt K, Rana S, Misra P, Chakraborti PK. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem Biophys Res Commun 1996;226:362-8. https://doi.org/10.1006/bbrc.1996.1362
  25. Meier A, Heifets L, Wallace RJ Jr, Zhang Y, Brown BA, Sander P, et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996;174:354-60. https://doi.org/10.1093/infdis/174.2.354
  26. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011;55:775-81. https://doi.org/10.1128/AAC.00861-10
  27. Nessar R, Reyrat JM, Murray A, Gicquel B. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 2011;66:1719-24. https://doi.org/10.1093/jac/dkr209
  28. Monego F, Duarte RS, Biondo AW. gyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from Southern Brazil. Microb Drug Resist 2012;18:1-6. https://doi.org/10.1089/mdr.2011.0047

Cited by

  1. Diagnosis of Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease in Korea vol.77, pp.1, 2014, https://doi.org/10.4046/trd.2014.77.1.1
  2. Mycobacterium abscessus Lung Disease in a Patient with Kartagener Syndrome vol.77, pp.3, 2014, https://doi.org/10.4046/trd.2014.77.3.136
  3. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex vol.10, pp.10, 2014, https://doi.org/10.1371/journal.pone.0140166
  4. In VitroAntimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran vol.22, pp.2, 2016, https://doi.org/10.1089/mdr.2015.0134
  5. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease vol.31, pp.5, 2014, https://doi.org/10.3346/jkms.2016.31.5.649
  6. Invasion of Mammalian Cells by Rough Variant of Mycobacterium abscessus vol.46, pp.4, 2014, https://doi.org/10.4167/jbv.2016.46.4.193
  7. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives vol.79, pp.2, 2016, https://doi.org/10.4046/trd.2016.79.2.74
  8. Resazurin Microtiter Assay for Clarithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group vol.30, pp.5, 2016, https://doi.org/10.1002/jcla.21933
  9. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm (41) gene: case report vol.16, pp.None, 2016, https://doi.org/10.1186/s12879-016-1554-7
  10. Infections caused byMycobacterium abscessus: epidemiology, diagnostic tools and treatment vol.14, pp.12, 2014, https://doi.org/10.1080/14787210.2016.1238304
  11. Mycobacterium abscessus Complex Infections in Children: A Review vol.19, pp.11, 2014, https://doi.org/10.1007/s11908-017-0597-2
  12. Relationship between Antibiotic Susceptibility and Genotype in Mycobacterium abscessus Clinical Isolates vol.8, pp.None, 2014, https://doi.org/10.3389/fmicb.2017.01739
  13. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease vol.64, pp.3, 2014, https://doi.org/10.1093/cid/ciw724
  14. Mycobacterium abscessus glycopeptidolipids inhibit macrophage apoptosis and bacterial spreading by targeting mitochondrial cyclophilin D vol.8, pp.8, 2017, https://doi.org/10.1038/cddis.2017.420
  15. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus vol.61, pp.9, 2017, https://doi.org/10.1128/aac.02752-16
  16. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics vol.2018, pp.None, 2014, https://doi.org/10.1155/2018/4902941
  17. Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm (41) vol.73, pp.4, 2014, https://doi.org/10.1093/jac/dkx476
  18. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii vol.62, pp.4, 2018, https://doi.org/10.1128/aac.01788-17
  19. Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates vol.62, pp.9, 2018, https://doi.org/10.1128/aac.00527-18
  20. Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast T vol.13, pp.11, 2014, https://doi.org/10.1371/journal.pone.0208053
  21. Genetic Correlation of Antibiotic Susceptibility and Resistance Genotyping for the Mycobacterium abscessus Group vol.63, pp.1, 2014, https://doi.org/10.1128/aac.01523-18
  22. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance vol.57, pp.8, 2019, https://doi.org/10.1128/jcm.00516-19
  23. Failure among Patients with Non-Tuberculous Mycobacterial Infections in Skin, Soft Tissue, and Musculoskeletal System in Southern Taiwan, 2012-2015 vol.20, pp.6, 2019, https://doi.org/10.1089/sur.2018.314
  24. Treatment of Mycobacterium abscessus Pulmonary Disease vol.94, pp.4, 2019, https://doi.org/10.3904/kjm.2019.94.4.343
  25. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches vol.13, pp.9, 2014, https://doi.org/10.1080/17476348.2019.1638765
  26. Antimicrobial Susceptibility of Mycobacterium abscessus Complex Clinical Isolates from a Chinese Tertiary Hospital vol.13, pp.None, 2014, https://doi.org/10.2147/idr.s252485
  27. Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela vol.39, pp.3, 2020, https://doi.org/10.1007/s10096-019-03740-7
  28. 16S and 23S rRNA Gene Mutation Independent Multidrug Resistance of Non-Tuberculous Mycobacteria Isolated from South Korean Soil vol.8, pp.8, 2020, https://doi.org/10.3390/microorganisms8081114
  29. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus vol.65, pp.12, 2014, https://doi.org/10.1128/aac.01514-21